CUV Share Price

Open 7.67 Change Price %
High 7.84 1 Day 0.20 2.62
Low 7.58 1 Week -0.21 -2.61
Close 7.84 1 Month -0.03 -0.38
Volume 53597 1 Year 4.97 173.17
52 Week High 9.19
52 Week Low 2.60
CUV Important Levels
Resistance 2 8.08
Resistance 1 7.98
Pivot 7.75
Support 1 7.70
Support 2 7.60
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
AKK 0.01 0.00%
TON 0.09 -10.00%
TON 0.09 -10.00%
TON 0.09 -10.00%
FAR 0.07 0.00%
FAR 0.07 0.00%
FAR 0.07 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
PMQ 0.03 50.00%
OMH 0.18 28.57%
SRZ 0.05 25.00%
SRZ 0.05 25.00%
HGO 0.05 25.00%
HGO 0.05 25.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
GBA 0.02 -33.33%
DAU 0.02 -33.33%
More..

Clinuvel Pharmaceuticals Ltd (ASX: CUV)

CUV Technical Analysis 3
As on 7th Dec 2016 CUV Share Price closed @ 7.84 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4.97 & Buy for SHORT-TERM with Stoploss of 7.37 we also expect STOCK to react on Following IMPORTANT LEVELS.
CUV Target for December
1st Target up-side 8.62
2nd Target up-side 9.01
3rd Target up-side 9.41
1st Target down-side 7.48
2nd Target down-side 7.09
3rd Target down-side 6.69
CUV Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.clinuvel.com
CUV Address
CUV
190 Queen Street
Level 14
Melbourne, VIC 3000
Australia
Phone: 61 3 9660 4900
Fax: 61 3 9660 4999
CUV Latest News
Shares in Focus: Clinuvel Pharmaceuticals Limited (ASX:CUV)   Marion Business Daily   - 06th Dec 16
Short Interest Report: CLINUVEL PHARM ADR (OTCMKTS:CLVLY) Sellers Increased By ...   Post News   - 30th Nov 16
Clinuvel Pharmaceuticals Ltd prepares for new drug application in the US   Proactive Investors Australia   - 09th Nov 16
What's in Clinuvel Pharmaceuticals Limited After Reaching 52-Week High?   Frisco Fastball   - 20th Oct 16
FDA, CLINUVEL to Discuss SCENESSEĀ® at Pre-NDA Meeting   GlobeNewswire (press release)   - 13th Oct 16
Clinuvel Pharmaceuticals Ltd fulfils pre-clinical safety of vitiligo drug   Proactive Investors Australia   - 03rd Aug 16
Clinuvel to file new drug with FDA   GlobeNewswire (press release)   - 18th Jul 16
Clinuvel Pharmaceuticals Ltd given fast track drug status by FDA   Proactive Investors Australia   - 06th Jul 16
Clinuvel Pharmaceuticals to offer treatment for light-induced disorder   Proactive Investors Australia   - 02nd Jul 15
PEG Ratio (5 yr expected):   Yahoo!7 News   - 29th Mar 14
Interactive Technical Analysis Chart Clinuvel Pharmaceuticals Ltd ( CUV ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Clinuvel Pharmaceuticals Ltd
CUV Business Profile
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of skin disorders in Australia. Its lead drug compound is SCENESSE, a photoprotective drug for the treatment of erythropoietic protoporphyria, which has completed Phase II and III trials. The SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation and sunlight. It is also involved in the research of CUV9900, an alpha-melanocyte stimulating hormone (alpha-MSH) analogue. The company is headquartered in Melbourne, Australia.